Oral Breviscapine slow release preparation
The present invention relates to a kind of medicine that is used for the treatment of the special form of cardiovascular and cerebrovascular disease.
Chinese patent application CN1053609A (application number 9010045.0) discloses a kind of " extraction process of Breviscapine crude drug ", this technology is with Herba Erigerontis Herb coarse powder, through the ethanol lixiviate, with the alcohol extract concentrating under reduced pressure, emit concentrate, behind the hot water extraction, with Acid precipitation, the deacidification removal of impurity, the portable lighter small cup florigen crude product refining of going forward side by side obtains the breviscapine elaboration.
Breviscapine (Brevescapine) extracts from feverfew Erigeron breviscapus (Vant.) Hand.-Mazz. (Erigeron Breviscapus (Vant.) Hand.-Mazz.), and its former plant beginning is stated from " the southern regions of the Yunnan Province book on Chinese herbal medicine ", original name Herba Erigerontis (being Herba Erigerontis again).Breviscapine is a yellow powder, dissolves in caustic liquor, is slightly soluble in methanol, water insoluble, chloroform etc., tool faintly acid.Breviscapine is based on scutellarin, and contains the mixture of a small amount of breviscapine, and its Main Ingredients and Appearance is scutellarin (Scutellarin), accounts for 95%, its formal name used at school is 4 ', 5,6-trihydroxyflavone-7-glucuronide.Prove through pharmacological research, breviscapine has expansion of cerebral vascular, reduce cerebral vascular resistance, the cerebral blood flow increasing amount, microcirculation improvement improves blood-brain barrier permeability, the immunization of enhancing body macrophage phagocytic, resist pituitrin institute to cerebral hypoxia ischemia, and can resist the platelet aggregation effect that causes by adenosine diphosphate (ADP) (ADP).Breviscapine is widely used in disease such as paralyse after the uncertain apoplexy of treatment cerebral thrombosis, cerebral infarction and type clinically.
At present, the Breviscapine of Ying Yonging has injection, injectable powder granule and conventional tablet clinically, injection, injectable powder are mainly used in the cerebrovascular treatment of acute stage, and granule and conventional tablet are mainly used in cerebrovascular convalescent period, the treatment of sequela stage and the prevention of cerebrovascular thereof.
As everyone knows, the quality of the pharmaceutical preparations of a medicine can greatly influence the clinical value of this medicine, which kind of preparation no matter, its enter in the body back blood concentration must be in treatment window scope the normal therapeutical effect of competence exertion, low invalid, high generation toxicity.Find that after deliberation the breviscapine solubility property is poor, for water does not dissolve, oily indissolubility medicine, the dissolubility of breviscapine in organic solvent is also very little.It is insoluble substantially in normal hexane and chloroform, and the dissolubility in the water is 14mg/L, and the dissolubility in ethanol is 5.8g/L, is a special insoluble drug.Oil/water partition coefficient the P=0.073 of breviscapine in ethyl acetate-water, the oil in n-octyl alcohol-water/water partition coefficient P=0.063.Moreover, breviscapine still is a weak acidic drug, make the absorption variation owing to dissociating at intestinal, so the bioavailability of breviscapine is low, its absolute bioavailability (=AUCpo/AUCiv*100%) only be 16.2%.Breviscapine oral administration biological half-life short (about about 2 hours), the bioavailability of its plain particles agent and conventional tablet is low, the effective blood concentration weak point of holding time, and its indication cerebrovascular is a chronic disease, it is big to cure difficulty, and its convalescent period and sequela stage treatment cycle are long.Therefore must adopt heavy dose of multiple dosing just can reach therapeutic purposes clinically, not only cause blood drug level " peak valley " wave phenomenon, and bring very big trouble to patient, simultaneously since exist easily miss with take medicine night blanking time long and can not keep the therapeutic effect that effective blood drug level and performance continue, the blind area on the curative effect occurs, aspect clinical efficacy, wild effect is arranged.
Purpose of the present invention is intended to overcome the deficiencies in the prior art, provides a kind of and prolongs action time, reduces the medication number of times, reduces side effect and improve the oral Breviscapine slow release preparation of the bioavailability of preparation with different release mechanism.
Oral oil lamp pollenin slow releasing preparation of the present invention is characterized in that containing solubilizing composition 10-80%, the blocker 5-70% of breviscapine of percentage by weight and the pharmaceutic adjuvant of surplus.
The solubilizing composition of breviscapine of the present invention can be the solid dispersion of breviscapine-soybean lecithin (or lecithin) complex, breviscapine, the cyclodextrin clathrate of breviscapine, the micronised powder of breviscapine or the compositions of breviscapine and solubilizing agent, can be wherein any one, also can be the combination of described several arbitrary proportions.
Pharmaceutic adjuvant of the present invention comprises emulsifying agent, PH regulator, filler, wetting agent, fluidizer and lubricant.
The content of the breviscapine solubilizing composition 10%-80% that is weight percentage in the described preparation, with 30%-70% is good, the content of the blocker 5%-70% that is weight percentage, with 15%-50% is good, the content of the emulsifying agent 1%-30% that is weight percentage, the content of the PH regulator 6%-50% that is weight percentage.
Described blocker can be hydroxypropyl emthylcellulose (HPMC such as HPMC K4M, HPMC K100, HPMC E50, HPMC E5, HPMC E4M, HPMC K15M, HPMC K50M, HPMC K100M etc.), ethyl cellulose (EC such as EC 7, EC 10, EC 20 etc.), Carbopol (as Carbopol 934p and sodium salt thereof, Carbopol 971p etc.), sodium carboxymethyl cellulose (CMC-Na), hydroxyethylmethyl-cellulose (HEMC), methylcellulose (MC), hydroxyethyl-cellulose (HEC), hydroxypropyl cellulose (HPC), fatty acid and fatty acid ester are (as oleic acid, oleyl alcohol, stearic acid, stearyl alcohol, cholic acid, medium chain triglycerides, glyceryl monostearate etc.) etc. one or more in.
The used adjuvant of preparation solid dispersion can be Polyethylene Glycol (PEG such as PEG4000, PEG6000 etc.), polyvinylpyrrolidone (PVP such as PVP-K30 etc.), low-viscosity hydroxypropyl emthylcellulose (low-viscosity HPMC such as HPMC-E50 HPMC-E5 etc.), Poloxamer 188 (Pluronic F68 etc.), one or more in the surfactant etc.
The used adjuvant of preparation cyclodextrin clathrate can be a beta-schardinger dextrin-, hydroxypropyl, ethoxy beta-schardinger dextrin-, one or more in the Methyl flamprop.
Solubilizing agent can be medicinal surfactant Tween (as Tween-80), sodium lauryl sulphate, Cremophor RH40, Poloxamer etc. and PH regulator.
The PH regulator can be one or more faintly acids or alkalescence cushions such as amino acid salts, phthalate, phosphate (as Na2HPO4, NaH2PO4 etc.), citrate, acetic acid and acetate, tartrate.
Emulsifying agent can be surfactant (as Tween-80, sodium lauryl sulphate, Tween-85, Mrij35, Migyol 30, Tagat TO, Migyol 812 etc.), soybean lecithin, one or more in oleic acid and oleate, oleyl alcohol, cholic acid and the cholate etc.
Filler, wetting agent, fluidizer and lubricant are the medicinal adjuvant of conventional formulation production.
The solubilizing composition of breviscapine of the present invention can adopt following method preparation:
(1), breviscapine is adopted micronization pulverize.
(2), adopt fusion method or solid dispersion preparations such as solvent method or solvent fusion method to prepare the breviscapine solid dispersion.
(3), adopt saturated solution method or clathrate preparation methoies such as freeze-drying or spray drying method to prepare cyclodextrin clathrate of breviscapine.
(4), in breviscapine, add pro rata solubilizing agent stirring and make it mix homogeneously.
(5), breviscapine and soybean lecithin are scattered in the non-protonic solvent preparation breviscapine-soybean lecithin complex.
The Breviscapine slow release preparation of the present invention's preparation is the oral sustained release dosage form, and the index of its quality control mainly is bioavailability and biological effect.Product of the present invention is as long as under the condition of technology unanimity, certain retardance material has repeatability preferably to the release of medicine.
The quality standard of product release of the present invention is that onset time of physicochemical property, pharmacological action, the minimal effective concentration according to breviscapine, the minimum blood concentration that toxic and side effects occurs, clinical requirement and drug effect duration etc. work up the release standard, to guarantee that safety of clinical administration is effective.The stability of product of the present invention also meets the requirements.
Carry out animal experiment with product of the present invention, meet two-compartment model through evidence product physiological disposition of the present invention, AUC is 18.4884 (ug/ml)
*Hr and the AUC of ordinary preparation is 9.3167 (ug/ml)
*Hr, product of the present invention is higher nearly one times than ordinary preparation bioavailability, and the peak value of blood drug level maintains in the effective blood drug concentration scope, and is comparatively steady, and the blood concentration fluctuation coefficient is little.Can confirm by following zoopery result:
Animal experiment: common rabbit (overnight fasting, can't help water) 12, male and female half and half, body weight 2.32 ± 0.25kg, be divided into 2 groups at random, irritate the complete preparation of stomach respectively by the 60mg/kg body weight: Breviscapine slow release tablet 1 (containing scutellarin 60mg) or 3 of ordinary tablets (every contains scutellarin 20mg, altogether 60mg), 50mL pours water behind the filling stomach.Respectively at irritate behind the stomach 0.25,0.5,1.0,2.0,3.0,6.0,7.0,12.0,24.0,48.0h takes ear vein blood 1mL.Blood sample adds 1% anticoagulant heparin, and-20 ℃ are saved to mensuration after the separated plasma.The time of twice intersection filling stomach was 1 week.
Extract scutellarin in the blood plasma, carry out determination of plasma concentration in the experimental animal body, draw blood drug level-time graph, see Fig. 1 with high pressure lipuid chromatography (HPLC).
Utilize the 3p87 program, two chamber model match pharmacokinetic parameters.The results are shown in Table 1.
Oil lamp pollenin slow releasing preparation of the present invention has following characteristics:
(1) adopt the gentle controlled-release technology of solid dispersion technology to increase the bioavailability of breviscapine in the preparation, prolonging its effective blood concentration holds time, blood drug level " peak valley " wave phenomenon of avoiding frequent drug administration to cause, make blood drug level steady, medicine increases relatively and stablizes in the concentration of pathological tissues, improve curative effect, timeliness and patient's compliance, thereby reach the safe and effective purpose of convenient treatment again.
(2) it is good to have a medicine-releasing performance, and blood drug level is characteristics stably, and release mechanism that can be different prolongs action time, reduces the medication number of times, reduces side effect.
(3) it is good to have a drug absorption, preparation biological the high characteristics of expenditure.
(4) it is good to have a product stability, the characteristics that technology repeatability height and mechanization degree are high.And the production equipment of available routine and prepared, the mechanization degree height, output is big, cost is low and be convenient to transportation preserves.
Fig. 1 is preparation plasma concentration curve figure of the present invention.
Table 1 is preparation of the present invention (SRT) and conventional formulation (CT) kinetic parameter table.
Among the figure:
Be Breviscapine slow release tablet (STR),
Be breviscapine ordinary preparation (CT), (n=6).
Be embodiments of the invention below, but content of the present invention is not limited thereto.
Embodiment 1: component content (percentage by weight) breviscapine-HPMC E50 solid dispersion 70.0%
HPMC?K4M 10.0%
Lactose 18.0%
Magnesium stearate 1%
95% ethanol is an amount of
Preparation method: preparation breviscapine-HPMC E50 solid dispersion: in breviscapine (50.0%), add Tween-80 (10.0%), an amount of 95% ethanol in proportion, be scattered in behind the mixing in the fused HPMC E50, adopt the solvent fusion method to make breviscapine-HPMC E50 solid dispersion.Add pharmaceutic adjuvants such as blocker at breviscapine-HPMC E50 solid dispersion, by after certain PROCESS FOR TREATMENT, mix homogeneously adds an amount of 95% ethanol preparation soft material, granulate, dry below 60 ℃, granulate, get particle inspection qualified after, add an amount of magnesium stearate, tabletting behind the mix homogeneously.The qualified back packing of quality examination, labeling, packing promptly gets the Breviscapine slow release tablet.
Embodiment 2:
Component content (percentage by weight)
Breviscapine-Tween-80 solubilizing agent compositions 10.0%
HPMC E50 (or E5) 50.0%
HPMC?K4M 5.0%
Lactose 30.0%
Magnesium stearate 1.0%
95% ethanol is an amount of
Preparation method: the solubilizing agent compositions of preparation breviscapine: in breviscapine, add Tween-80 (solubilizing agent) mixing in proportion promptly.Solubilizing composition at breviscapine adds blocker pharmaceutic adjuvants such as (HPMC E50 HPMCK4M), by after certain PROCESS FOR TREATMENT, mix homogeneously adds an amount of 95% ethanol preparation soft material, granulate, dry below 60 ℃, granulate, get particle inspection qualified after, add magnesium stearate, tabletting behind the mix homogeneously (also can add pharmaceutic adjuvants such as blocker and filler, fluidizer, lubricant, direct compression behind the mix homogeneously) by after certain PROCESS FOR TREATMENT.The qualified back packing of quality examination, labeling, packing promptly gets the Breviscapine slow release tablet.
Embodiment 3:
Component content (percentage by weight)
Breviscapine-Benexate Hydrochloride 80.0%
HPMC E50 (or E5) 10.0%
HPMC?K4M 8.0%
Sodium lauryl sulphate 1.0%
Magnesium stearate 1.0%
95% ethanol is an amount of
Preparation method: preparation breviscapine-Benexate Hydrochloride: after in breviscapine, adding sodium lauryl sulphate, an amount of ethanol in proportion, be scattered in the beta-schardinger dextrin-beta-schardinger dextrin-, adopt saturated solution method to make cyclodextrin clathrate.In breviscapine-Benexate Hydrochloride, add blocker pharmaceutic adjuvants such as (HPMC E50 HPMC K4M), by after certain PROCESS FOR TREATMENT, mix homogeneously adds an amount of 95% ethanol preparation soft material, granulate, dry below 60 ℃, granulate, get particle inspection qualified after, add magnesium stearate, tabletting behind the mix homogeneously (also can add pharmaceutic adjuvants such as blocker and filler, fluidizer, lubricant, direct compression behind the mix homogeneously) by after certain PROCESS FOR TREATMENT.The qualified back packing of quality examination, labeling, packing promptly gets the Breviscapine slow release tablet.
Embodiment 4:
Component content (percentage by weight)
Breviscapine-soybean lecithin complex 40.0%
HPMC E50 (or E5) 15.0%
EC?10(EC?20) 10.0%
Na2HPO4 (PH regulator) 25.0%
NaH2PO4 (PH regulator) 3.5%
Magnesium stearate 2%
95% ethanol is an amount of
Preparation method: preparation breviscapine-soybean lecithin complex: breviscapine and soybean lecithin are scattered in non-knowing clearly property of the matter solvent make in proportion.In the solubilizing composition of breviscapine, add blocker (HPMCE50, EC 10 or EC 20) as acetone and pharmaceutic adjuvant, by after certain PROCESS FOR TREATMENT, mix homogeneously adds an amount of 95% ethanol preparation soft material, granulate, dry below 60 ℃, granulate, get particle inspection qualified after, add magnesium stearate, tabletting behind the mix homogeneously (also can add pharmaceutic adjuvants such as blocker and filler, fluidizer, lubricant, direct compression behind the mix homogeneously) by after certain PROCESS FOR TREATMENT.The qualified back packing of quality examination, labeling, packing promptly gets the Breviscapine slow release tablet.
Embodiment 5:
Component content (percentage by weight)
Breviscapine solubilizing agent compositions 65.0%
HPMC E50 (or E5) 20.0%
Lactose 14.0%
Magnesium stearate 1.0%
Preparation method: the preparation breviscapine increase the molten compositions of agent: in the breviscapine alcoholic solution, add Mrij 35, Tween-80, soybean lecithin in proportion, add oleic acid (or cholic acid, stearic acid), oleyl alcohol (or stearyl alcohol, medium chain triglycerides, glyceryl monostearate) behind the mix homogeneously, be prepared into the solubilizing composition of breviscapine.Solubilizing composition at breviscapine adds blocker HPMC E50 (or E5) etc., and by after certain PROCESS FOR TREATMENT, filled capsules is made slow releasing capsule.The qualified back packing of quality examination, labeling, packing promptly gets erigeron breviscapus slow release capsule.
Embodiment 6:
Component content (percentage by weight)
Breviscapine solubilizing agent compositions 70.0%
HPMC E5 (or E50) 15.0%
Carbopol-934p 15.0%
Preparation method: the solubilizing agent compositions of preparation breviscapine: in the breviscapine alcoholic solution, add Mrij35, Tween-80, soybean lecithin in proportion, add oleic acid (or cholic acid, stearic acid), oleyl alcohol (or stearyl alcohol, medium chain triglycerides, glyceryl monostearate), Poloxamer behind the mix homogeneously, be prepared into the solubilizing composition of breviscapine.Solubilizing composition at breviscapine adds blocker HPMC E50 (or E5), Carbopol-934p etc., and by after certain PROCESS FOR TREATMENT, pelleting is made the slow release soft gelatin capsule.The qualified back packing of quality examination, labeling, packing promptly gets the Breviscapine slow release soft gelatin capsule.
Embodiment 7:
Component content (percentage by weight)
The micronised powder 30.0% of breviscapine
HPMC E50 (or E5) 50.0%
HPMC?K4M 5.0%
Microcrystalline Cellulose 10.0%
95% ethanol is an amount of
Magnesium stearate 1.0%
Preparation method: the micronised powder of preparation breviscapine: placing the heavy pulverizer of gas to be ground into micronised powder breviscapine, is less than 5 μ carefully.In the micronised powder of breviscapine, add blocker (HPMC E50HPMC K4M) and pharmaceutic adjuvant, by after certain PROCESS FOR TREATMENT, mix homogeneously adds an amount of 95% ethanol preparation soft material, granulate, dry below 60 ℃, granulate, get particle inspection qualified after, add magnesium stearate, tabletting behind the mix homogeneously (also can add pharmaceutic adjuvants such as blocker, filler, fluidizer, lubricant, direct compression behind the mix homogeneously) by after certain PROCESS FOR TREATMENT.The qualified back packing of quality examination, labeling, packing promptly gets the Breviscapine slow release tablet.
Parameter | Unit |
SRT
|
CT
|
A
|
ug/ml
|
-0.3138
|
-0.2756
|
Alpha
|
l/hr
|
3.2164
|
3.4994
|
B
|
ug/ml
|
0.4104
|
0.1286
|
Beta
|
l/hr
|
0.0404
|
0.0148
|
Ka
|
l/hr
|
0.0229
|
0.2080
|
V/f(c)
|
(mg)/(ug/ml)
|
1.3745
|
13.3891
|
t1/2alpha
|
hr
|
0.2155
|
0.1981
|
t1/2 beta
|
hr
|
77.4799
|
46.8203
|
k21
|
l/hr
|
-0.006
|
0.1077
|
k10
|
l/hr
|
2.3610
|
0.4810
|
k12
|
l/hr
|
0.8569
|
2.9255
|
AUC
|
(ug/ml)
*hr
|
18.4884
|
9.3167
|
CL(s)
|
mg/hr/(ug/ml)
|
3.2453
|
6.4401
|
T(peak)
|
hr
|
1.6200
|
1.0800
|
C(max)
|
ug/ml
|
0.2998
|
0.2377
|
t1/2ka
|
l/hr
|
30.2108
|
3.3326
|
Table 1